Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity.
Tan QW, Vankadara S, Fong JY, See YY, Baburajendran N, Ng PS, Xu W, Yeo YK, Wang W, Low CH, Tan LH, Ju Tay EG, Wong YX, Huang C, Sim S, Ang SH, Min Toh HH, Mohammad J, Wang G, Liu B, Tan ST, Kwek PZ, Dawson MD, Oh QY, Koh X, Joy J, Lee MA, Stunkel W, Pendharkar V, Hentze H, Lim SP, Ethirajulu K, Brian Chia CS, Cherian J.
Tan QW, et al. Among authors: ang sh.
J Med Chem. 2025 Aug 28;68(16):17087-17102. doi: 10.1021/acs.jmedchem.5c00581. Epub 2025 Aug 7.
J Med Chem. 2025.
PMID: 40773370